Lincoln Pharmaceuticals (NSE:LINCOLN, BOM:531633) posted a rise in attributable consolidated profit to 286.0 million Indian rupees in the fiscal third quarter ended Dec. 31, 2025, from 207.7 million rupees a year ago, according to an Indian bourse filing on Thursday.
Earnings per share climbed to 14.28 rupees compared with 10.37 rupees a year earlier.
Revenue from operations in fiscal Q3 increased year on year to 1.66 billion rupees from 1.47 billion rupees.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.